|
|
Phase II Study of Antineoplastons A10 and AS2-1 in Adults With Primary Malignant Brain Tumors
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Registry Information
Alternate Title
Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors
Basic Trial Information
Phase | Type | Status | Age | Protocol IDs |
---|
Phase II | Treatment | Active | 18 and over | BC-BT-21 NCT00003475 |
Objectives - Provide antineoplastons A10 and AS2-1 as treatment for patients with incurable primary malignant brain tumor that has progressed during or is recurrent or persistent after prior standard therapy, including radiotherapy and/or chemotherapy.
- Describe the response to, tolerance to, and side effects of this regimen in these patients.
Entry Criteria Disease Characteristics:
- Histologically or cytologically confirmed incurable primary malignant
brain
tumor that has progressed during or is recurrent after prior initial
therapy,
including radiotherapy
- Failed prior standard therapy
- Measurable disease by MRI or CT scan
- No brain stem tumors
Prior/Concurrent Therapy:
Biologic therapy: - At least 4 weeks since prior immunotherapy
- No concurrent immunomodulating agents
Chemotherapy: - At least 4 weeks since prior chemotherapy, except in patients with
disease progression during initial therapy
- At least 6 weeks since prior nitrosoureas, except in patients with
disease progression during initial therapy
- No concurrent antineoplastic agents
Endocrine therapy: Radiotherapy: - See Disease Characteristics
- At least 8 weeks since prior radiotherapy, except in patients with
disease progression during initial therapy
Surgery: - At least 4 weeks since prior surgery, except in patients with
disease progression during initial therapy
Other: - Recovered from prior therapy
- Cytodifferentiating agents allowed
Patient Characteristics:
Age: Performance status: Life expectancy: Hematopoietic: - Hematological function normal
- WBC at least 2000/mm3
- Platelet count at least 50,000/mm3
Hepatic: - No liver failure
- No evidence of hepatic insufficiency
- Bilirubin no greater than 2.5 mg/dL
- SGOT/SGPT no greater than 5 times upper limit of normal
Renal: - No evidence of renal insufficiency
- Creatinine no greater than 2.5 mg/dL
- No history of renal conditions that contraindicate high
dosages of sodium
Cardiovascular: - No uncontrolled hypertension
- No history of congestive heart failure
- No chronic heart failure
- No other cardiovascular conditions that contraindicate high
dosages of sodium
Pulmonary: - No serious lung disease, such as severe chronic obstructive pulmonary disease
Other: - Not pregnant or nursing
- Fertile patients must use effective contraception during and
for 4 weeks after study participation
- No medical or psychiatric illness that would preclude study
treatment
- No active infection
Expected Enrollment 40Approximately 20-40 patients will be accrued for this study. Outcomes Primary Outcome(s)Response rate based on tumor measurements taken at 12 weeks
Secondary Outcome(s)Survival at 1, 2, and 5 years from the start of treatment
Outline Patients receive gradually escalating doses of intravenous
antineoplastons A10 and AS2-1 6 times per day until the maximum tolerated dose is
reached. Treatment continues for at least 3 months in the absence of disease
progression or unacceptable toxicity. Patients achieving complete response
(CR) continue treatment for an additional 8 months after reaching CR. Patients are followed at least every 2 months for 1 year, every 3 months for the second year, every 3-4 months for the third and fourth years, every 4-6 months for the fifth year, and then annually thereafter.
Trial Contact Information
Trial Lead Organizations Burzynski Clinic | | | Stanislaw Burzynski, MD, PhD, Protocol chair | | | | Trial Sites
Registry Information | | Official Title | | Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Primary Malignant Brain Tumors | | Trial Start Date | | 1996-02-26 | | Trial Completion Date | | 2011-12-31 (estimated) | | Registered in ClinicalTrials.gov | | NCT00003475 | | Date Submitted to PDQ | | 1998-07-29 | | Information Last Verified | | 2008-12-21 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|